

February 9, 2021

To,
SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sirs,

Re: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to consider repurchase of Foreign Currency Debt

- A. We hereby inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, a meeting of the Board of Directors of Glenmark Pharmaceuticals Limited ("Company") will be held on February 12, 2021, to consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.\$200 million (as on date outstanding U.S.\$ 113.5 million) 2 per cent resetttable onward starting equity linked securities due June 28, 2022 issued in 2016 ("FCC Bonds"), based on market opportunities and conditions from time to time and to delegate powers to operations committee. The Operations Committee, based on market opportunities and conditions, will hold meetings to consider and approve the terms and conditions of any tenders or buybacks.
- B. This is for the information of your members and all concerned in compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended.

The above is for your information.

Thanking you

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary Compliance Officer

Tel: 4018 9999 / 4018 9879
Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com